FDA argues Lynparza only works in prostate cancer subset – Fierce Pharma
The FDA suggests that in prostate cancer, Lynparza is only appropriate for BRCA-mutant cases.
The FDA suggests that in prostate cancer, Lynparza is only appropriate for BRCA-mutant cases.
